CMV IgM

A positive CMV IgM result needs context, especially if you're pregnant. It can reflect a first infection, a repeat infection, antibodies that have lingered, or a false-positive reaction. The distinction matters because a first infection during pregnancy can pass to the baby and cause lasting hearing loss or developmental problems.

Cytomegalovirus is a common herpes family virus that stays in your body after infection. Most healthy people have no symptoms. CMV IgM is an established part of investigating a possible recent infection, but a positive result alone cannot establish when infection happened or whether it is causing disease.

How the Antibody Rises and Fades

IgM is one of the early antibody responses to a first infection. CMV IgG usually develops soon afterward and remains detectable long term. IgM often declines over the following months, though the timing varies between people and between laboratory tests.

Some people remain IgM-positive for more than a year. Older studies also documented persistence for up to two years in some kidney transplant recipients. Those findings came from particular assays and populations, so they don't provide a timetable for your own result.

IgM can also appear during reactivation of an existing infection or infection with a different strain. A positive result therefore doesn't necessarily mean this is your first encounter with the virus.

Why a Positive Result Often Isn't a Recent First Infection

IgG avidity measures how firmly IgG antibodies bind to the virus. That binding usually strengthens during the months after a first infection, which makes avidity useful for interpreting a positive IgM.

A French retrospective study examined 6,859 IgM-positive serum samples. The proportion classified as recent first infections using low IgG avidity depended on why testing had been done.

These were results from one laboratory's testing pathway, not universal probabilities for every positive report. The ultrasound group was particularly small. The remaining samples did not meet the study's avidity criteria for a recent first infection; that does not establish whether each represented lingering antibody, a repeat infection, or a false-positive reaction.

Pregnancy and Congenital Infection

An infection passed to a baby during pregnancy can cause hearing loss, impaired growth, an abnormally small head, or developmental disabilities. Many infected babies have no symptoms at birth. Severe consequences are most strongly associated with maternal infection early in pregnancy, although transmission can occur later.

A first maternal infection carries a higher transmission risk than a repeat infection, but prior infection doesn't provide complete protection. Babies can acquire CMV after maternal reactivation or reinfection, including when maternal IgM is negative.

In a Turkish case series, all nine pregnancies with confirmed fetal infection had negative maternal IgM when assessed. These were selected cases evaluated later in pregnancy, so they cannot establish how often screening misses infection. They do show why a negative maternal IgM cannot dismiss fetal findings that suggest CMV. Negative IgM and high avidity later in pregnancy also cannot prove that infection happened before conception.

The amount of IgM in your blood does not establish whether your baby is infected or predict how severely a baby might be affected.

Mono-Like Illness in Healthy Adults

Most first CMV infections in healthy adults cause no recognized illness. When symptoms occur, they can include prolonged fever and fatigue, sometimes with increased lymphocytes and raised liver enzymes. Lymphocytes are a type of white blood cell. These findings also occur with other infections.

IgM can help investigate this kind of illness when interpreted with other results. A small multihospital study of hospitalized adults documented uncertainty about whether positive IgM represented a first CMV infection, reactivation, or a false-positive result. An antibody result alone may not explain your symptoms.

Transplants, HIV, and Weakened Immunity

CMV can cause serious disease when immunity is weakened, including inflammation of the retina, lungs, or bowel. After transplantation, infection can also be associated with graft complications and other infections.

Antibody responses can be delayed or reduced in this setting. IgM is not recommended for diagnosing or monitoring active CMV infection after an organ transplant. Transplant monitoring relies on CMV DNA testing in blood, together with symptoms and, when needed, examination of affected tissue.

HIV care differs. Routine monitoring of CMV DNA in blood is not recommended for people with HIV, and a negative blood DNA result does not exclude disease in an organ. CMV retinitis is usually diagnosed through a dilated eye examination; suspected disease elsewhere may require tissue testing.

What the Long-Term Health Studies Measured

Studies linking CMV to heart disease or shorter life have generally measured IgG evidence of past infection. That is a different antibody from the IgM measured here. A large British population cohort of more than 10,000 adults associated IgG positivity and higher IgG levels with higher death rates. An analysis of about 8,500 UK Biobank participants found no association with cardiovascular disease after accounting for other risk factors, and pooled data from older white adults found no association with death from any cause or cardiovascular death.

These observational findings do not establish that CMV caused the outcomes, and they do not validate IgM as a measure of aging or long-term cardiovascular risk.

When Results Can Be Misleading

• Other infections: Epstein-Barr virus can produce a misleading CMV IgM result. In one study, 40 of 149 children with primary Epstein-Barr infection tested positive for both viruses' IgM antibodies. Only one of those 40 met the study's criteria for true CMV coinfection. Those pediatric findings are not a universal false-positive rate.
• Overlapping antibody signals: A hepatitis E study found that about a quarter of hepatitis E IgM-positive samples also had CMV IgM. Most hepatitis E IgM-positive samples were not confirmed by viral RNA testing, so this does not show that a quarter of confirmed hepatitis E infections cause false-positive CMV results. A separate retrospective study associated SARS-CoV-2 antibodies with CMV IgM positivity, but cross-reactivity was a possible explanation rather than a proven mechanism.
• Interfering antibodies: Rheumatoid factor and other antibodies can interfere with some CMV IgM assays. The effect depends on the test design. An autoimmune diagnosis alone is not enough to dismiss a positive result.
• Immune suppression: Treatment regimens containing mycophenolate can reduce CMV IgM production. Immune suppression can also increase susceptibility to CMV disease, so a weak antibody response does not imply that the infection is mild.
• Different laboratory kits: Commercial tests differ in which samples they call positive and how long they continue detecting IgM after infection. A comparison of four platforms found substantially more disagreement for IgM than for IgG. Results from different kits are not interchangeable.
• Timing: IgM may be absent before an antibody response develops, may disappear unusually early, or may not develop detectably. In a French study of confirmed early first infections during pregnancy, about 3% had negative or borderline IgM on the platform studied.

What the Reported Number Means

This test reports CMV IgM in AU/mL. These are arbitrary units on the laboratory's antibody scale. The number does not measure how much virus is present, how contagious you are, or the severity of an infection. The laboratory's interpretation, companion antibody results, symptoms, and timing provide the clinical context.